CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Berlin, Germany and 66 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Berlin, Germany and 73 other locations
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...
Phase 3
Berlin, Germany and 186 other locations
of BCL6 (BCL6 LDD), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin...
Phase 1, Phase 2
Berlin, Germany and 21 other locations
monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least tw...
Phase 2
Berlin, Germany and 44 other locations
B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this stud...
Phase 1
Berlin, Germany and 26 other locations
This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma...
Phase 2, Phase 3
Berlin, Germany and 76 other locations
cancer treatment and have also shown first encouraging results in Non-Hodgkin lymphomas. Based on these observations it is...
Berlin, Germany and 13 other locations
in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem ...
Phase 2
Berlin, Germany and 53 other locations
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this dise...
Phase 3
Berlin, Germany and 271 other locations
Clinical trials
Research sites
Resources
Legal